Zydus Cadila gets USFDA nod for generic antiviral drug, Atazanavir capsules

Topics Zydus Cadila | HIV Aids | USFDA

The Zydus Group now has 291 approvals and has so far filed over 390 abbreviated new drug application (ANDAs) since the commencement of the filing process in 2003-04

Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Atazanavir capsules, an antiviral drug, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to market Atazanavir capsules in strengths of 150 mg, 200 mg and 300 mg, Zydus Cadila said in a statement.

Atazanavir, an antiretroviral drug, is used to treat Human Immunodeficiency Virus (HIV-1) infection incombination with other antiretroviral drugs.

 

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The Zydus Group now has 291 approvals and has so far filed over 390 abbreviated new drug application (ANDAs) since the commencement of the filing process in 2003-04, the company said.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel